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Traditional public health methods for detecting infectious 
disease transmission, such as contact tracing and molecular 
epidemiology, are time-consuming and costly. Information 
and communication technologies, such as global position-
ing systems, smartphones, and mobile phones, offer op-
portunities for novel approaches to identifying transmission 
hotspots. However, mapping the movements of potentially 
infected persons comes with ethical challenges. During an 
interdisciplinary meeting of researchers, ethicists, data se-
curity specialists, information and communication technol-
ogy experts, epidemiologists, microbiologists, and others, 
we arrived at suggestions to mitigate the ethical concerns of 
movement mapping. These suggestions include a template 
Data Protection Impact Assessment that follows European 
Union General Data Protection Regulations.
Human and pathogen co-evolution has led to a vast ar-ray of transmission routes, transmission dynamics, and 
risks for infection. Human behavior, particularly movement 
between locations, plays a primary role in the transmission 
dynamics of infectious diseases (1). Geospatial areas with 
high prevalence or efficient transmission of disease are 
known as hotspots (2). Transmission hotspots can be thought 
of as nodes in space and time where the density of contact 
between infected and uninfected persons is higher than aver-
age, increasing the risk for disease transmission. 
Interrupting transmission is key to preventing and 
controlling infectious diseases (1). Timely identification of 
transmission routes and hotspots is necessary for tailoring 
public health interventions. However, many interventions 
that effectively break transmission chains also invade the 
private sphere of affected persons or communities and of-
ten are at odds with personal liberties (3). Some methods of 
identifying transmission hotspots could reveal sensitive in-
formation on behavior and the inner functioning of a com-
munity, making these methods problematic from an ethics 
point of view.
Traditional public health approaches to mapping hu-
man-to-human transmission routes include contact tracing 
and molecular epidemiology. Both approaches are labori-
ous, costly, and limited. Contact tracing, in which investiga-
tors follow up with named contacts to identify those at risk 
for exposure (4), lacks sensitivity for population-based in-
terruption of transmission chains. Molecular epidemiology 
uses genetic typing of pathogens isolated from patients to 
trace transmission by highlighting genetic similarity (5) but 
is prone to undersampling, potentially missing key events in 
complex transmission chains. Because of laboratory delays, 
molecular epidemiology frequently does not lead to action-
able findings. In addition, this method is not feasible outside 
of research institutions in many low- and middle-income 
countries, where higher rates of infectious diseases occur.
A promising alternative to contact tracing is to iden-
tify transmission hotspots where public health workers can 
tailor preventive strategies. During an infectious disease 
outbreak, as control increases in the general population, 
the disease typically spreads heterogeneously. Transmis-
sion events then concentrate in areas and communities not 
reached by conventional approaches. 
When the goal is elimination and ultimate eradica-
tion of a specific disease, tackling transmission hotspots 
is key. Information and communication technology (ICT), 
such as global positioning systems (GPS), smartphones, 
and mobile phones, could provide a novel approach to 
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identifying transmission hotspots (Appendix 1, http://ww-
wnc.cdc.gov/EID/article/25/7/18-1421-App1.pdf). One 
promising approach is to map movements of persons by 
using ICT data to identify behavior patterns and transmis-
sion hotspots where cost-effective prevention strategies 
could be implemented. This type of mapping could reduce 
transmission of diseases that are difficult to eliminate, such 
as tuberculosis (TB), leprosy, schistosomiasis, malaria 
(6), and sleeping sickness, and assist in controlling out-
breaks of acute disease, such as Ebola virus (7,8), cholera, 
or Shiga toxin–producing Escherichia coli O157:H7 (9). 
However, mapping the movements of potentially infected 
persons comes with many ethical challenges.
We proposed a project in which researchers request 
informed consent from TB patients to map their aggre-
gate movements through their cellular phone call detail 
records (CDRs). In the context of this project, we con-
vened a 1-day meeting on the ethical aspects around 
the use of mobility data for mapping infectious disease 
transmission. The meeting, held October 24, 2017, at 
the Institute of Tropical Medicine (Antwerp, Belgium), 
included researchers, ethicists, data security specialists, 
ICT experts, epidemiologists, microbiologists, and a rep-
resentative from a national TB program (Appendix 2, 
http://wwwnc.cdc.gov/EID/article/25/7/18-1421-App2.
pdf). The objective for the 20 participants was to consider 
risks and benefits of using ICT data to map movements 
of infected persons and identify transmission hotspots 
of TB and other infectious diseases. From this meeting, 
we developed a model Data Protection Impact Assess-
ment (DPIA) template that others can use to conduct a 
similar assessment (Appendix 3, http://wwwnc.cdc.gov/
EID/article/25/7/18-1421-App3.pdf). We focused mainly 
on ethical aspects for research but also addressed specific 
concerns that could arise if the approach is scaled up for 
programmatic use.
Data Sources for Detecting  
Transmission Hotspots
Information on case mobility, typically collected by public 
health officials or researchers through patient interviews, 
is crucial for tracking pathogen transmissions. However, 
the limited population sample interviewed introduces se-
lection bias. In addition, questionnaire data on mobility 
might lack sufficient detail and are prone to both recall 
and information bias. Because of the complexity and cost, 
interviews and questionnaires are difficult to implement 
in programmatic conditions and do not allow for real-time 
interpretation using autonomous self-learning algorithms. 
The global penetration of mobile phones could provide 
a viable means to track infectious diseases by electroni-
cally mapping case mobility data. Worldwide, 66% of the 
population used mobile phones in 2017, counting unique 
mobile subscribers and corrected for use of multiple sub-
scriber identification module (SIM) cards. Of global SIM 
cards, 57% are used in smartphones, without correcting for 
multiple SIM card users (10). We discussed 3 options for 
collecting ICT data: a dedicated smartphone application,a 
separate GPS tracking device, and mobile phone call re-
cords (Table; Appendix 1).
Ethical Issues of Mobility Mapping
Collecting mobility data linked to health information pos-
es specific challenges for upholding ethics principles de-
scribed in basic guidelines for human subjects research. We 
see 2 highly relevant ethical obstacles: protecting the par-
ticipants’ privacy in relation to principles of autonomy and 
nonmaleficence and finding a balance between costs, risks, 
and benefits for participants and communities in relation to 
principles of beneficence and justice (11).
Protecting Participants’ Privacy
The European Union General Data Protection Regula-
tion (EU GDPR, EU Regulation 2016/679) (12) and 
Guideline 22 of the Council for International Organiza-
tions of Medical Sciences (13), among other regulations, 
explicitly stress the need for protecting the privacy and 
confidentiality of persons and their information. In all 
situations, investigators must put protective measures 
in place to avoid breaches in confidential mobility data 
that might cause unintended inferences about a user’s 
life (14).
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Table. Characteristics of different approaches to collecting mobility data for mapping infectious disease outbreaks* 
Characteristics 
Source of mobility data 
Dedicated smartphone application GPS tracker Call detail records 
Scalability to large populations Medium Low High 
Retrospective analysis possible Likely, depending on stored location 
data on phone at time of installation 
No Likely, depending on duration of data 
storage at telecom operators 
Spatial resolution High, depending on mobile data use 
and WiFi density 
High Variable, depending on cell tower and 
mast density 
Participant control Medium High Low 
Third party access to private 
information 
Possibly Unlikely Likely 
Need for uninfected controls  Possibly Unlikely Likely, to avoid identification of health 
information by telecom operators 
*GPS, global positioning system. 
 
 Ethical Considerations for Movement Mapping to Identify Disease Transmission Hotspots 
Outbreaks of highly infectious diseases, such as Ebola 
and cholera, along with endemic diseases, such as HIV and 
TB, are more prevalent in low-income countries. Many mo-
bility tracking approaches have been implemented to iden-
tify infectious disease hotspots in these areas (6,15–19). 
In international collaborations, researchers from abroad 
should apply the same ethics and regulatory standards they 
would apply in their own countries. EU-funded researchers 
working outside the EU must ensure their research adheres 
to EU GDPR standards. Mapping across national boundar-
ies might require further ethics and data security safeguards 
and the perceived balance between benefit and risk of map-
ping mobility might be different in diverse social and cul-
tural contexts.
In some circumstances, investigators might have dif-
ficulty meeting ethics requirements for informed consent. 
Waivers for informed consent can be granted by the con-
cerned ethics committees, but only under exceptional cir-
cumstances; for instance, during outbreaks, if the research 
is low-risk and has potential for high societal value; if ob-
taining written consent is unpractical or unfeasible; and if 
data anonymization and other adequate measures are in 
place to mitigate confidentiality and privacy risks.  
Linking health conditions or diagnoses with patient 
movements constitutes a high risk to infected persons. 
Consequently, investigators should not have access to the 
movements of individual patients, and telecommunications 
staff should not be able to link movements of persons with 
their health-related information. Participants should be 
aware of these risks when asked for their telephone data. 
They also should be informed of their right to refuse or 
withdraw their consent for use of their data.
The challenges are even greater for mapping move-
ments of children. Most children do not routinely keep 
mobile phones; great cultural and socioeconomic varia-
tions exist in the age of first phone use and in adult super-
vision. Children under a certain age presumably would be 
accompanied by adults. Just as in other kinds of research, 
minors should be asked for assent when their parent or 
guardian is asked for informed consent, according to their 
capacity and maturity, while adhering to local regulatory 
requirements. Additional ethics challenges might arise if 
parents or guardians request access to the mobility data of 
their children.
Costs, Risks, and Benefits for  
Participants and Communities
In public health ethics, the dilemma of individual risk 
versus population benefit is well-recognized (20,21). 
When weighing risks to participants’ privacy against 
potential population benefits, researchers must consider 
the participants’ status. Patients, contacts of patients, or 
healthy persons sampled from the general population 
will have different risks to their privacy or benefits for 
their communities. 
Study participants will not directly benefit from know-
ing where they might have acquired or spread an infectious 
disease. Therefore, the realistic potential of a study to con-
tribute to improved public health must be considerable to 
outweigh the risk to the participant. Spatiotemporal analy-
sis of data can show where infected persons crossed paths 
when they were infectious but is not proof of actual trans-
mission events. These data can indicate locations where the 
density of infected persons was higher and might point to 
previously unsuspected transmission hotspots.
Communities or neighborhoods with confirmed or sus-
pected infectious disease transmission hotspots might be 
stigmatized. Such stigma could have further negative con-
sequences, such as discrimination against groups or neigh-
borhoods, reduced tourism (22), or decreased property 
values. Although anonymized data can focus on neighbor-
hoods rather than specific buildings, stigma could occur at 
businesses, schools, social venues, or healthcare facilities 
in an area identified as a transmission hotspot. Research-
ers should consider such risks and plan adequate mitigat-
ing measures during protocol development and should in-
clude representatives from involved communities during 
protocol development. Community representatives can 
provide a firsthand understanding of local challenges, such 
as the community’s perception of the disease; whether spe-
cific persons are typically stigmatized in the community; 
whether persons could be legally prosecuted for behaviors 
associated with disease transmission, such as drug use or 
same sex intercourse in some areas; and how to provide in-
formation back to the community. Researchers should not 
presume that they can identify representative community 
leaders. In some contexts, leaders are obvious, such as pa-
tients with HIV or TB who are active in local associations, 
but identifying these leaders might be more difficult in ur-
ban settings or in disrupted communities under the stress 
of an outbreak.
In contrast to the ethical risks, researchers also should 
consider whether withholding the vast amount of mobility 
data would be unethical and whether an ethical imperative 
exists to use the available data for maximal benefit (23). 
Ultimately, if residual risk is acceptable, analysis of mobil-
ity data can be justified if it can yield actionable insights 
that benefit public health.
Researchers also should consider whether, and how, 
to communicate information on hotspots to the general 
population. In doing so, they must question whether public 
health interventions in the hotspots are sufficient to reduce 
the risk for infection for persons moving into and out of 
those areas. If so, avoiding communication about specific 
hotspots could reduce the chance for stigma in that com-
munity. On the other hand, if persons moving into or out of 
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hotspots need to take protective measures, such as wearing 
a mask or avoiding the area altogether, then researchers 
should put the utmost care into communicating appropri-
ate messages.
Mitigating Ethical Challenges
During the protocol design phase, researchers should as-
sess the risk-benefit balance of their intended movement 
mapping strategy, address risks for privacy breaches, and 
plan for mitigating such breaches. The Global System for 
Mobile Communications Association and others have de-
veloped guidelines and outlined ethical challenges for us-
ing telecommunication data (24–27). However, no single 
framework will fit the myriad of movement mapping ap-
proaches or all applications for the identification of trans-
mission hotspots of infectious diseases.
According to the EU GDPR, personal data can only be 
processed under specific circumstances for a well-defined 
and communicated purpose, and only when participants 
consent and data processing is proportionate to the purpose 
(12). Personal data cannot be processed beyond what is 
known or expected by the research participant and cannot 
be kept longer than needed.
A DPIA provides a framework to mitigate risks by tak-
ing privacy principles into account in the earliest concep-
tion and engineering phases of a project or data process-
ing application (Appendix 3). Along with an analysis of 
residual risks, researchers should conduct a DPIA before 
beginning data collection.
Involving Communities as Research Stakeholders
Including the community and its members as stakehold-
ers during the design phase will help investigators con-
vey the public health benefits of the project and minimize 
misunderstanding, mistrust, and panic. To maintain ac-
countability to communities, researchers should involve 
them in the preparation, implementation, and evalua-
tion of aggregate movement mapping data. By working 
with community members, investigators can address 
concerns about risks and benefits to the community and 
its members. 
Potential approaches to enhancing community input 
include involving community advisory boards or similar 
community structures in the study protocol design (28,29); 
carrying out a preliminary qualitative study to investigate 
the perception of local policy makers and members of the 
community about the mobility data collection; or carrying 
out a rapid ethics assessment, a brief qualitative interven-
tion used to examine the ethics terrain of a research set-
ting before recruiting participants (30). Such participatory 
research approaches engage communities in the research 
process and take local perception into account during re-
search planning (29). 
To further reduce the chance of stigmatization of 
the neighborhoods or groups, researchers should install 
measures to prevent identification of transmission 
hotspot locations by outside parties. Such measures 
could include confidentiality agreements with local pub-
lic health authorities and communication plans to reduce 
the consequences of misuse of information by the media 
or other actors.
Aggregating Data
Researchers should use aggregate analyses of mobility data 
to reduce the risk of breaching participants’ privacy and 
confidentiality (24,25). This process could involve anony-
mizing phone numbers associated with CDRs so that pa-
tient information can be viewed without revealing identities 
or phone numbers of participants. In addition, researchers 
can use algorithms that permit aggregate analysis of a mini-
mum number of participants’ CDRs to reduce the chance of 
pinpointing a participant’s movements. Aggregate CDRs 
provide background mobility controls, while still calculat-
ing relative risks of transmission hotspots. In the absence 
of aggregate CDRs, investigators can still identify hotspots 
with few relative risks to participants’ privacy.
Requesting Informed Consent
Informed consent and patient information sheets should 
be transparent, specific, and unambiguous. The aim is to 
guide participants’ understanding of the project’s purpose, 
as well as how investigators will handle their personal data, 
protect their confidentiality, and address any residual risks 
to personal information after the study. During the con-
sent interview or in the consent documentation, research-
ers should reduce jargon and present information in plain 
language appropriate for the audience. Investigators also 
might use teach-back methods, back translation, and pilot 
testing with the target group to assist in developing accu-
rate informed consent and patient information sheets. 
Participants should be informed how long their data 
will be stored before destruction and the deadline by which 
they can request rectification or destruction of their data. A 
rapid ethics assessment also can help improve the design 
of the informed consent tools for a given population. Study 
personnel should be properly trained on the informed con-
sent and data collection procedures. 
Considerations for Telecommunications 
Regulatory Authorities and Providers
In addition to ethics approvals, the telecommunication 
regulatory authorities must approve use of CDRs and mo-
bile phone companies will require confidentiality and data 
transfer agreements. Researchers will need to ensure that 
mobile network operators and their employees comply with 
the same confidentiality rules applied in the health sector, 
e4 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 7, July 2019
 Ethical Considerations for Movement Mapping to Identify Disease Transmission Hotspots 
including securely handling, storing, and limiting access 
to data. Agreements with mobile phone companies should 
specify that they not share data with other parties or retain 
it longer than necessary.
One way to minimize the chance for mobile network 
employees or others to link CDRs to a particular disease 
profile is through recruiting uninfected participants as con-
trol cases. Researchers can include uninfected participants’ 
CDRs, with their consent, from the same catchment area 
as the patients. Control participants benefit public health 
without gaining a personal benefit, but they face the same 
risk for confidentiality breaches. In addition, such breaches 
could cause them to be mistaken as infected with the dis-
ease. No clear precedent exists to help set a dilution rate 
(i.e., the ratio of uninfected controls to patients) to suffi-
ciently mitigate the chances of linking a person with an in-
fectious disease diagnosis. However, more controls might 
favorably shift the risk-benefit balance.
For data analysis, researchers should use algorithms 
that prevent disaggregation of data and reduce opportu-
nities to link health information and mobility patterns 
with any participant’s identity. After aggregating the 
analysis, investigators can filter out controls to arrive at 
hotspot information.
Communicating Information on 
Transmission Hotspots
When researchers publish study findings, they should clearly 
demonstrate that they followed all ethics rules and discussed 
a response plan with local communities and public health au-
thorities, especially when they discuss a previously unknown 
public health problem in a specific community. To avoid re-
vealing exact locations, researchers can include graphical 
representations rather than recognizable maps. Researchers 
also can request to override any requirements for sharing the 
full or aggregated dataset and associated metadata at the time 
of publication due to privacy concerns. 
Regardless of safeguards, the media, authorities, or 
politicians could misuse published results or take the find-
ings out of context. Although a data transfer agreement 
with a mobile network will not prevent misuse of infor-
mation, researchers can reduce negative consequences of 
such misuse by developing a comprehensive communica-
tion plan with community stakeholders and public health 
authorities before starting the project.
Researchers should have an adequate understanding 
of the mobile technologies and related ethics require-
ments for each specific research project. Ethics com-
mittees might lack the knowledge and expertise to as-
sess these protocols correctly and researchers should be 
prepared to explain the technologies and how they can 
benefit public health. In addition, ethics committees and 
institutional review boards should consider involving data 
security specialists as more research begins to incorporate 
mobile technologies.
Implementing Mobile Mapping
After a research project demonstrates the feasibility of ethi-
cally using CDRs for identifying transmission hotspots, a 
national control program might choose to implement it. 
For a TB program, patients with confirmed TB could pro-
vide informed consent to release their CDRs to map their 
movements. Staff from the national TB program could pe-
riodically perform an aggregate analysis of recent CDRs to 
identify locations where transmission might have occurred. 
In addition to ethics issues tackled during research, 
public health programs could encounter more ethics 
complexities. For instance, patients might experience a 
therapeutic misconception and feel obliged to consent to 
releasing their CDRs if the request comes from the same 
physician who is providing healthcare because they fear 
care will be withheld if they do not consent. Also, pro-
grams should be aware that routine surveillance data 
could be used for retrospective research, blurring the 
boundary between surveillance and research. Even if 
such surveillance is not intended as research, a public 
health program should involve the appropriate ethics 
committee. The ethics committee can assess the proto-
col for collecting mobility data and the informed consent 
tool, as well as the proposed project’s public engage-
ment and transparency plans to determine its benefit to 
the public (31).
Conclusions
With their unprecedented global penetration, mobile 
phones can yield vast amounts of information that offer 
opportunities for mapping infectious disease hotspots but 
also pose ethical challenges. We offer suggestions on safe-
guards to ensure data can be used to benefit public health 
while protecting the users’ privacy and confidentiality. 
The EU GDPR protects EU residents and participants in 
EU-funded research in countries outside of the EU from 
abuse of personal information. The higher standards for the 
EU GDPR also apply to the ethics framework for research 
on mobility patterns conducted for public health benefits. 
By upholding these ethics standards, public health inves-
tigators could use mobility mapping to identify infectious 
disease transmission hotspots without compromising the 
privacy of patients or creating mistrust in communities af-
fected by infectious diseases.
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